D.Western Therapeutics Institute, Inc.【JP:4576】Cash flow
Market cap
¥4.5B
P/E ratio
-6.7x
De Western Therapeutics Institute develops protein kinase inhibitor drugs for eye diseases and licenses them to pharmaceutical companies for commercialization.
| 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Depreciation & amortization | 3 | 18 | 45 | 52 | 44 | 44 | 45 | 46 | 49 | 49 | 48 |
| Cash from operations | -323 | -334 | -797 | -540 | 176 | -216 | -176 | -355 | -587 | -1,299 | -494 |
| Capital expenditures | -1 | -37 | -4 | -6 | - | -5 | -2 | -10 | -12 | -9 | -3 |
| Cash from investing | 835 | -231 | -763 | -8 | -100 | -13 | -111 | -140 | -15 | -10 | -2 |
| Repurchases of common stock | - | - | - | - | - | - | - | - | - | - | - |
| Proceeds from issuance of term debt, net | - | - | 582 | - | - | 100 | - | 13 | 166 | 226 | 135 |
| Repayments of term debt | - | - | - | - | -120 | -120 | -120 | -120 | -120 | -10 | -25 |
| Cash from financing | 88 | 1,067 | 1,407 | - | -120 | 1,004 | -104 | 867 | 134 | 568 | 1,080 |
| Free cash flow | - | ||||||||||
| FCF margin (%) | - |